CSI Market
Sign In | Register

Emergent Biosolutions Inc (EBS) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access EBS Annual Cash Flow →
By examining cash flow figures across successive periods, users can identify shifts in Emergent Biosolutions Inc's cash generation and deployment strategy.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-173.40
Depreciation & amortization47.50
Amortization of Other Assets37.10
Increase (Decrease) in Deferred Revenue0.00
Impairment of Long-Lived Assets Held-for-use191.30
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-39.80
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total-12.70
Share-based Compensation8.80
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-29.40
Change In Fair Value Of Contingent Obligations-
Write Off Of Bank Fees-
Gain Loss On Disposition Of Property-
Impairment Of Accrued Interest On Note Receivable-
Change In Fair Value Of Contingent Consideration-
Increase Decrease In Long Term Incentive Plan Accrual0.40
Capital Expenditures Incurred But Not Yet Paid1.00
Increase Decrease In Contract With Customer Liability3.20
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable91.70
Increase (Decrease) in Accounts Payable-4.40
Increase (Decrease) in Accrued Liabilities1.20
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.60
Other Working Capital0.00
Other Noncash Income (Expense)-19.80
Other net0.00
Payments for (Proceeds from) Other Operating Activities-76.40
Discontinued operations0.00
Net Cash flow from Operating Activities22.30
Investing Activities
Capital Expenditures-4.50
Sale of Capital Items0.20
Proceeds from Sale and Maturity of Available-for-sale Securities0.00
Payments to Acquire Available-for-sale Securities, Debt0.00
Real Estate Investments0.00
Proceeds From Sale Of Other Assets-
Payment For Contingent Consideration Liability Investing Activities-
Payments For Proceeds From Contingent Consideration Liability Asset Investing Activities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments for Previous Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses, Net of Cash Divested0.00
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net-50.40
Discontinued operations0.00
Net Cash Flow from Investing Activities-54.70
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-11.50
Long-term debt - borrowings145.50
Long-term debt - repayments-150.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-16.60
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-3.20
Other net0.00
Contingent Value Right Payment-
Proceeds From Borrowings On Long Term Indebtness And Line Of Credit-
Principal Payments On Long Term Indebtness And Line Of Credit-
Payment Attributed To Contingent Value Rights-
Proceeds From Borrowings On Long- Term Indebtedness-
Proceeds From Borrowings On Long Term Indebtedness And Line Of Credit-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents209.10
Proceeds Allocated To Common Stock Issued In Conjunction With Debt-
Payments For Repurchase Of Debt-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-35.80
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow18.00
Total Cash Flow-68.20
4 historic quarters locked

Sign in to unlock the full Emergent Biosolutions Inc cash flow history.

Sign In Create Free Account

About Emergent Biosolutions Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 5, 2026
  • Source: ebs-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001367644-26-000082

Figures are derived from filed reports and may be restated. Historical data is subject to revision.